U.K. Watchdog Says GSK Infringed Competition Law With “Pay-For-Delay” Deals
This article was originally published in The Pink Sheet Daily
Executive Summary
The U.K.'s Office of Fair Trading is proceeding with its action against GlaxoSmithKline, alleging it held back generic competition to its best-selling antidepressant paroxetine from 2001 to 2004 through agreements with generic drug firms.